4D Molecular Therapeutics, Inc. FDMT
Regular-session close
After hours · Nov 19, 5:55 PM ET
- YTD
- +42.93%
- 1 year
- -0.74%
5D -1.94 (-15.26%)
- Market cap
- 604.39M
- Revenue (ttm)
- 17.00K
- EPS (ttm)
- -2.70
- Shares out
- 46.23M
- Forward P/E
- -1.79
- YTD return
- +42.93%
- 1-year return
- -0.74%
- 50-day average
- 7.82
- Volume
- 755.23K
- Avg volume
- 984.18K
- Open
- 10.97
- Previous close
- 10.46
- Day's range
- 10.40 – 11.02
- 52-week range
- 6.96 – 16.93
- Analysts
- Buy
- Price target
- 42.64 (+297.7%)
Key statistics
- 200-day average
- 17.94
- Price / sales
- 15989.35
- Price / book
- 0.82
- Revenue growth
- -100.00%
- Short % of float
- 19.19%
Fundamental scorecard
9 of 25 checks passed on FDMT’s reported financials
9of 25 checks passed
- Value 2 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.67 | -0.79 | -0.12 | -17.91% |
| Aug 8, 2024 | Jun 1, 2024 | -0.72 | -0.63 | +0.09 | +12.50% |
| Aug 8, 2024 | Jun 1, 2024 | -0.72 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.73 | -0.66 | +0.07 | +9.59% |
| May 9, 2024 | Mar 1, 2024 | -0.73 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | -0.68 | -0.77 | -0.09 | -13.24% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 2024 | B of A Securities | main | Buy | Buy |
| Nov 21, 2024 | Morgan Stanley | init | — | Underweight |
| Nov 14, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2024 | RBC Capital | main | Outperform | Outperform |
| Sep 23, 2024 | Cantor Fitzgerald | down | Overweight | Neutral |
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- 4dmoleculartherapeutics.com
News
4D Molecular Therapeutics, Inc. (FDMT) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Tops Revenue Estimates 4D Molecular Therapeutics Q3 EPS $(1.08) Misses $(1.05) Estimate, Sales $4.100M Beat $2.700M Estimate
4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics, Inc. (FDMT) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Now Rated “Moderate Buy” by Wall Street Brokerages
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy
Your note
Sign in to keep a note on FDMT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIZILY SCOTT | Officer | Sale | Sep 15, 2024 | 6,781 |
| CHACKO JACOB M | Director | Sale | Apr 20, 2023 | 0 |
| KIM ROBERT YOUNG | Officer | Sale | Feb 4, 2024 | 1,043 |
| KIRN DAVID | Chief Executive Officer | Sale | Jul 9, 2024 | 1,059,150 |
| MORETTI AUGUST J | Chief Financial Officer | Conversion of Exercise of derivative security | May 14, 2023 | 11,045 |
| VIKING GLOBAL INVESTORS LP | Beneficial Owner of more than 10% of a Class of Security | Sale | Jan 3, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 15.97% | 7,382,642 | 43.41M | Sep 29, 2024 |
| RA Capital Management, L.P. | 11.03% | 5,098,211 | 29.98M | Sep 29, 2024 |
| Blackrock Inc. | 10.53% | 4,868,789 | 28.63M | Sep 29, 2024 |
| VR Adviser, LLC | 9.52% | 4,400,000 | 25.87M | Sep 29, 2024 |
| Deep Track Capital, Lp | 8.86% | 4,096,452 | 24.09M | Sep 29, 2024 |
| Goldman Sachs Group Inc | 7.77% | 3,591,030 | 21.12M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.33% | 1,537,368 | 9.04M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.83% | 1,308,552 | 7.69M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.25% | 1,038,505 | 6.11M | Sep 29, 2024 |
| Janus Henderson Global Life Sciences Fund | 2.20% | 1,016,235 | 5.98M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.27% | 589,274 | 3.46M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.10% | 509,965 | 3.00M | Aug 30, 2024 |
